Taken together, these data confirm that inhibition of PTP1B by Claramine might be an efficient strategy to block not only IL13 but EGF-promoted Src activation in GBM cells, increasing the potential therapeutic value of PTP1B inhibitors. The gene discussed is EGF; the disease is glioblastoma.